Apeiron Biologics Ag

Other

Sandoz Gmbh

Attoquant Diagnostics Gmbh

Igeneon Krebs-immuntherapie Forschungs-und Entwicklungs-ag

Greenovation Biotech Gmbh

Meridian Biopharmaceuticals Gmbh

Medizinische Universitat Innsbruck

Apeiron Biologics Forschungs-und Entwicklungsgesellschaft M.b.h.

Igeneon Krebs-immuntherapie Forschungs-und Entwickungs-ag

Dr. Hans Loibner

Hans Loibner

Wolfgang Stoiber

Evotec Ag

Medizinische Universitaet Innsbruck

Manfred Schuster

Ruth Ladenstein

Oliver Mutschlechner

Evelyne Janzek-Hawlat

Bernhard Peball

Isabel Klier

Stefan Stranner

Helmut Eckert

Gottfried Himmler

Marko Poglitsch

Cornelia Schwager

Geert Mudde

Gerda Redl

Robert Weik

Manuela Loidl

Günther Lametschwandtner

Holger Lode

Günter Waxenecker

Thomas Putz

Bettina Wagner

Man Sung Co

Mark Whittaker

Pui Leng Loke

Michael Freissmuth

Russell Stuart Craft

Dieter Scholz

Ralf Kircheis

Harald Schnidar

Susanne Wiederkum

Franz Groiss

Gunther Lametschwandtner

Patricia Leonie Amouzegh

Severine Danielle Jones

Timothy Robin James

Wolfgang Streicher

Monika Ermann

Isabella Haslinger

Guenther Lametschwandtner

Sandra Seidl

Gottfried Baier

Dominik Wolf

Thomas Hanke

Guenter Waxenecker

Ina Sternberger

Anton Stuetz

Markus Klinger

Roland Wehr

Hesso Farhan

Peter St/u/ Tz

Patricia Léonie Amouzegh

Eugen Stermetz

Andreas Hauer

Hellmut Samonigg

The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2 wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is/are preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.

Preparations and methods for treating a GD2 positive cancer

A method of treating a high-risk neuroblastoma in a patient is described.

The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.

Method for treating a GD2 positive cancer

The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.

Method for measurement of peptidic degradation products of a proteolytic cascade in blood samples

The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life.

Method for producing ACE2 polypeptide

The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein Rto R, X, Xand Rhave the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising such compounds as well as their use as medicaments, especially in methods for the treatment or prevention of a neoplastic and/or infectious disease and in vitro methods. 

Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases

Preparations and methods for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2), and wherein one or more treatment periods with the antibody may be preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.

The present invention relates to a pharmaceutical composition comprising a. at least one aspartyl aminopeptidase inhibitor and at least one angiotensin-converting-enzyme (ACE) inhibitor, or b. at least one aspartyl aminopeptidase inhibitor and at least one chymase inhibitor. In an embodiment, the pharmaceutical composition comprises at least one aspartyl aminopeptidase inhibitor and at least one angiotensin-converting-enzyme (ACE) inhibitor and at least one chymase inhibitor. Furthermore, the invention relates to a pharmaceutical composition possessing inhibitory activity against a. aspartyl aminopeptidase and angiotensin-converting-enzyme (ACE), or b. against aspartyl aminopeptidase and chymase. In a third aspect, the invention relates to a kit of parts comprising a. a pharmaceutical composition comprising an aspartyl aminopeptidase inhibitor and a pharmaceutical composition comprising an angiotensin-converting-enzyme (ACE) inhibitor, or b. a pharmaceutical composition comprising an aspartyl aminopeptidase inhibitor and a pharmaceutical composition comprising a chymase inhibitor, or c. a pharmaceutical composition comprising an aspartyl aminopeptidase inhibitor and a pharmaceutical composition comprising an angiotensin-converting-enzyme (ACE) inhibitor and a pharmaceutical composition comprising a chymase inhibitor. The invention also relates to a method for decreasing the blood pressure in a subject by administering a therapeutically effective amount of a pharmaceutical composition according to the invention to the subject. In another aspect, the invention relates to a method for treating a disease related to the RAS in a subject by administering a therapeutically effective amount of a pharmaceutical composition according to the invention to the subject.

Compositions and methods for the treatment of diseases related to the renin-angiotensin-system

The present invention relates to preparations and methods for treating a GD2 positive cancer by administering a preparation comprising a chimeric or humanized anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with interleukin-2 (IL-2 wherein a GD2 positive cancer is treated in the patient. Furthermore, the invention relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein a preparation comprising an anti-GD2 antibody is administered to the patient as a continuous infusion, without concomitantly administering IL-2. The present invention further relates to preparations and methods for the treatment of a GD2 positive cancer in a patient, wherein the one or more anti-GD2 antibody treatment periods is/are preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.

The present invention relates to modified angiotensin converting enzyme 2 (ACE2) polypeptides and pharmaceutical and analytical uses thereof. In particular, the present invention relates to Zndepleted-, Znfree-, mixed metal- and metal ion substituted-ACE2 as well as methods for the manufacture of these variants and uses thereof, such as therapeutic and analytic uses of these ACE2 variants.

Modified ACE2 polypeptides

The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade (for example, the renin-angiotensin system (RAS) and the bradykinin system) in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.

The present invention relates to ACE2 for the therapeutic treatment or prevention of inflammation.

Treatment of inflammatory illnesses with ACE2

The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus permits the therapy of appropriate diseases.

SiRNA against Cbl-b and optionally IL-2 and IL-12 for use in the treatment of cancer

Growing community of inventors

Vienna, Austria

Hans Loibner